Bank of New York Mellon’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,640
| Closed | -$3.46K | – | 4156 |
|
|
2024
Q1 | $3.46K | Sell |
3,640
-18,787
| -84% | -$18.3K | ﹤0.01% | 4143 |
|
|
2023
Q4 | $24.9K | Sell |
22,427
-29,194
| -57% | -$43.4K | ﹤0.01% | 4218 |
|
|
2023
Q3 | $97K | Sell |
51,621
-797
| -2% | -$2.29K | ﹤0.01% | 4083 |
|
|
2023
Q2 | $188K | Sell |
52,418
-213
| -0.4% | -$673 | ﹤0.01% | 3995 |
|
|
2023
Q1 | $177K | Sell |
52,631
-606
| -1% | -$1.82K | ﹤0.01% | 3959 |
|
|
2022
Q4 | $82.5K | Sell |
53,237
-236
| -0.4% | -$350 | ﹤0.01% | 4154 |
|
|
2022
Q3 | $73K | Hold |
53,473
| – | – | ﹤0.01% | 4257 |
|
|
2022
Q2 | $117K | Sell |
53,473
-106,217
| -67% | -$244K | ﹤0.01% | 4193 |
|
|
2022
Q1 | $510K | Hold |
159,690
| – | – | ﹤0.01% | 3697 |
|
|
2021
Q4 | $669K | Sell |
159,690
-7,054
| -4% | -$39.6K | ﹤0.01% | 3616 |
|
|
2021
Q3 | $1.35M | Buy |
166,744
+11,105
| +7% | +$90.2K | ﹤0.01% | 3227 |
|
|
2021
Q2 | $1.18M | Sell |
155,639
-6,022
| -4% | -$50.7K | ﹤0.01% | 3303 |
|
|
2021
Q1 | $1.4M | Sell |
161,661
-38,055
| -19% | -$363K | ﹤0.01% | 3135 |
|
|
2020
Q4 | $1.59M | Buy |
199,716
+19,967
| +11% | +$167K | ﹤0.01% | 2976 |
|
|
2020
Q3 | $1.43M | Buy |
179,749
+23,989
| +15% | +$216K | ﹤0.01% | 2888 |
|
|
2020
Q2 | $1.54M | Sell |
155,760
-3,214
| -2% | -$29.5K | ﹤0.01% | 2832 |
|
|
2020
Q1 | $1.23M | Buy |
158,974
+38,293
| +32% | +$193K | ﹤0.01% | 2831 |
|
|
2019
Q4 | $465K | Buy |
120,681
+6,540
| +6% | +$28.5K | ﹤0.01% | 3628 |
|
|
2019
Q3 | $574K | Buy |
114,141
+14,146
| +14% | +$82.3K | ﹤0.01% | 3457 |
|
|
2019
Q2 | $661K | Sell |
99,995
-692
| -0.7% | -$4.75K | ﹤0.01% | 3457 |
|
|
2019
Q1 | $762K | Buy |
100,687
+3,357
| +3% | +$26.1K | ﹤0.01% | 3336 |
|
|
2018
Q4 | $786K | Buy |
97,330
+2,516
| +3% | +$25K | ﹤0.01% | 3240 |
|
|
2018
Q3 | $1.22M | Buy |
94,814
+11,666
| +14% | +$146K | ﹤0.01% | 3146 |
|
|
2018
Q2 | $948K | Buy |
83,148
+53,642
| +182% | +$508K | ﹤0.01% | 3275 |
|
|
2018
Q1 | $208K | Buy |
29,506
+4,311
| +17% | +$32.6K | ﹤0.01% | 3921 |
|
|
2017
Q4 | $164K | Sell |
25,195
-324
| -1% | -$2.06K | ﹤0.01% | 3988 |
|
|
2017
Q3 | $158K | Hold |
25,519
| – | – | ﹤0.01% | 3923 |
|
|
2017
Q2 | $110K | Sell |
25,519
-124
| -0.5% | -$544 | ﹤0.01% | 4008 |
|
|
2017
Q1 | $115K | Hold |
25,643
| – | – | ﹤0.01% | 3998 |
|
|
2016
Q4 | $140K | Sell |
25,643
-949
| -4% | -$5.2K | ﹤0.01% | 3966 |
|
|
2016
Q3 | $170K | Sell |
26,592
-2,877
| -10% | -$15K | ﹤0.01% | 3929 |
|
|
2016
Q2 | $134K | Sell |
29,469
-477
| -2% | -$2.08K | ﹤0.01% | 3992 |
|
|
2016
Q1 | $118K | Buy |
29,946
+11,065
| +59% | +$48K | ﹤0.01% | 3928 |
|
|
2015
Q4 | $105K | Hold |
18,881
| – | – | ﹤0.01% | 4047 |
|
|
2015
Q3 | $119K | Hold |
18,881
| – | – | ﹤0.01% | 4061 |
|
|
2015
Q2 | $116K | Buy |
18,881
+2,134
| +13% | +$14.5K | ﹤0.01% | 4014 |
|
|
2015
Q1 | $221K | Buy |
+16,747
| New | +$172K | ﹤0.01% | 3872 |
|
Other funds holding CTSO
AC
SC
GIM
SIG
CM
Bank of New York Mellon's CTSO Position: Q2 2024 in Review
Bank of New York Mellon sold out of Cytosorbents Corp (CTSO) in Q2 2024, closing a stake of 3,640 shares — an estimated $3.46K sold.
Bank of New York Mellon first reported a position in CTSO in Q1 2015 and held it in 37 quarters. The position peaked at $1.59M in Q4 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q2 2024.
- Bank of New York Mellon reported no remaining Cytosorbents Corp position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 3,640 Cytosorbents Corp shares in Q2 2024, an estimated $3.46K.
- Bank of New York Mellon first reported a position in Cytosorbents Corp in Q1 2015 and held it in 37 quarters.
- Bank of New York Mellon's Cytosorbents Corp position peaked at $1.59M in Q4 2020.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.